FDA offers new guidelines for Covid-19 vaccine

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more.

The need-to-know this morning

• Takeda reported negative results from two Phase 3 studies investigating the use of an experimental drug called soticlestat for the treatment of Dravet syndrome and Lennox-Gastaut syndrome — rare forms of epilepsy. Shares of Ovid Therapeutics, which had licensed soticlestat to Takeda, fell sharply in early trading.

More physicians are using ctDNA tests

Clinicians are increasingly using blood tests that measure circulating tumor DNA, or ctDNA, to figure out whether any cancerous cells remain after a malignancy is removed. One of the most popular ctDNA diagnostics is the Signatera test made by Natera; revenue for the company was up 52% in the last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In